Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Purpose
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Condition
- Prostatic Neoplasms
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Must have histologically or cytologically confirmed adenocarcinoma of the prostate - Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
Exclusion Criteria
- Prior treatment with an androgen receptor (AR) degrader - Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP - Clinically significant venous thromboembolism within 3 months prior to the first dose of IP - Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness Other protocol-defined inclusion/exclusion criteria apply
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Administration of CC-94676, CC1083611, and CC1083610 |
|
Recruiting Locations
Medstar Washington Hospital Center
Washington, District of Columbia 20010
Washington, District of Columbia 20010
Contact:
Suthee Rapisuwon, Site 122
216-773-2688
Suthee Rapisuwon, Site 122
216-773-2688
More Details
- Status
- Recruiting
- Sponsor
- Celgene
Study Contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
Clinical.Trials@bms.com